{
  "abstract": "Chimeric antigen receptor (CAR)‐T‐based strategies target the B‐cell maturation antigen (BCMA) expressed on the surface of malignant plasma cells in patients with multiple myeloma (MM). Idecabtagene vicleucel (ide‐cel), an anti‐BCMA CAR‐T therapy, has shown promising results in the treatment of relapsed or refractory multiple myeloma (R/RMM). Notably, the extent of CAR‐T cell expansion correlates with objective response rates and complete responses, indicating that monitoring CAR‐T cells is critical for predicting clinical outcomes in these patients. Although several tools are available to monitor CAR‐T cells in patient blood samples, they remain costly, prompting us to develop novel fluorescent and soluble BCMA reagents for CAR‐T cell labeling. BCMA is a type III transmembrane protein, and we found that a recombinant construct consisting of the BCMA extracellular domain fused to green fluorescent protein (GFP) failed to traffic through the Golgi apparatus and was not secreted. Incorporation of the interferon‐α2 signal peptide restored intracellular trafficking and enabled efficient secretion of soluble BCMA‐GFP and BCMA‐mCherry fusion proteins. These reagents specifically labeled anti‐BCMA CAR‐T cells. Overall, our results establish a cost‐effective method to generate soluble BCMA probes and provide accessible tools for monitoring CAR‐T cells in translational settings.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "name": "Ly Phuong Vy Nguyen"
    },
    {
      "name": "Christelle Oblet"
    },
    {
      "name": "Alice Barbarin"
    },
    {
      "name": "Louis Waeckel"
    },
    {
      "name": "Farah Kotaich"
    },
    {
      "name": "Clara Petit"
    },
    {
      "name": "Marine Mabily"
    },
    {
      "name": "Claire Carrion"
    },
    {
      "name": "André Herbelin"
    },
    {
      "name": "Jean-Marc Gombert"
    },
    {
      "name": "Xavier Leleu"
    },
    {
      "name": "Émilie Chalayer"
    },
    {
      "name": "Murielle Roussel"
    },
    {
      "name": "Patrick Legembre"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8eyyant53dxzm.bib",
  "cited_by": 0,
  "doi": "10.1002/eji.70251",
  "fulltext_url": null,
  "id": "8eyyant53dxzm",
  "issns": [
    "0014-2980",
    "1521-4141"
  ],
  "landing_url": "https://hal.science/hal-05713720v1",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.can"
    ],
    [
      "hal",
      "1.sdv.imm"
    ],
    [
      "hal",
      "1.sdv.mhep"
    ],
    [
      "hal",
      "2.sdv.imm.imm"
    ],
    [
      "hal",
      "2.sdv.mhep.hem"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7171784719",
  "pdf_url": "https://hal.science/hal-05713720/document",
  "pmcid": null,
  "pmid": "42528274",
  "published": "2026-09-01",
  "publisher": "Wiley-VCH Verlag",
  "ris": "https://research.draconitic.com/paper/8eyyant53dxzm.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:24Z",
      "native_id": "hal-05713720",
      "source": "hal",
      "url": "https://hal.science/hal-05713720v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:1.sdv.imm",
      "subfield": "immunology"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.can",
      "subfield": "oncology"
    }
  ],
  "title": "Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling",
  "title_text": "Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:24Z",
  "url": "https://research.draconitic.com/paper/8eyyant53dxzm",
  "venue": "European Journal of Immunology",
  "versions": []
}